Immodulon, the immuno-oncology company, today announces the appointment of Dr Michael Bowles, as Medical Director, with immediate effect. Dr Ruslan Croitoru has chosen to step down as Chief Medical Officer to pursue other interests. A search for a new CMO is underway. Dr Bowles is an experienced pharmaceutical physician with a particular interest in pharmacovigilance. He has held Medical Director and Medical Advisor positions in a range of pharmaceutical and biotech companies. Dr Bowles has worked as an independent consultant specialising in the provision of pharmaceutical medical services since 1998. He is a member of the British Association of Pharmaceutical Physicians and has acted as a Qualified Person (QP) and Deputy QP for pharmacovigilance in the European Union and has also held Association of the British Pharmaceutical Industry (ABPI) signatory responsibility for various companies.
Dr Jaap Kampinga, Chief Executive of Immodulon, commented:
“I am pleased that Michael, a medical advisor to the company for two years, has agreed to step into the role of Medical Director while we search for an appropriate replacement to Ruslan. Michael has significant experience in the pharmaceutical industry and will be invaluable to Immodulon as we work to further
advance Immodulon’s lead candidate, IMM-101. We would like thank Ruslan for his contribution to Immodulon and we wish him well in his future endeavours.”